On April 21 in Tbilisi the California biopharmaceutical company Gilead Sciences signed a historic agreement with the Government of Georgia to pilot a multi-year program to eliminate Hepatitis C from patients currently infected with the virus in Georgia.
With innovative medicine provided by Gilead Sciences, this life-changing program will cure an estimated 150,000 Georgians of their life-threatening Hepatitis C infection. Development and implementation of this program in Georgia will also provide an opportunity to develop a national model for addressing a serious health issue that affects 170 million people throughout the world.
Supported by the U.S. government’s Centers for Disease Control and Prevention (CDC), the elimination program is the fruit of close cooperation between Gilead Sciences, Georgia’s Ministry of Labor, Health, and Social Affairs and the Tbilisi-based National Center for Disease Control and Public Health. These agencies will jointly develop plans to carefully implement, monitor, and evaluate this historic public health program.